| Bioactivity | Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research[1]. |
| Invitro | Avdoralimab (IPH 5401) 选择性阻断人骨髓细胞中的 C5a-C5aR1 相互作用及其下游信号传导。在体外，用 Avdoralimab (10-30 μg/mL) 阻断 C5aR1 可抑制 C5a 诱导的中性粒细胞活化。Avdoralimab 阻断由非常高浓度的 C5a 诱导的嗜中性粒细胞活化。Avdoralimab 还在体外抑制 C5a 诱导的中性粒细胞迁移[1]。 |
| In Vivo | 在敲入人类 C5aR1 的小鼠（HuC5aR1 KI 小鼠）中，Avdoralimab 阻断嗜中性粒细胞和单核细胞的浸润，阻止白蛋白在支气管肺泡灌洗液 (BALF) 中的释放，并限制 C5a 诱导的急性肺损伤 (ALI) 组织病理学特征[1]。 |
| Name | Avdoralimab |
| CAS | 2226393-85-5 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Julien Carvelli, et al. Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020 Dec;588(7836):146-150. |